Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · Real-Time Price · USD
1.270
0.00 (0.00%)
Apr 25, 2025, 12:19 PM EDT - Market open
Akoya Biosciences Revenue
In the year 2024, Akoya Biosciences had annual revenue of $81.67M, down -15.48%. Akoya Biosciences had revenue of $21.34M in the quarter ending December 31, 2024, a decrease of -19.42%.
Revenue (ttm)
$81.67M
Revenue Growth
-15.48%
P/S Ratio
0.77
Revenue / Employee
$398,400
Employees
205
Market Cap
63.27M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
AKYA News
- 1 day ago - Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025 - GlobeNewsWire
- 1 day ago - Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas - GlobeNewsWire
- 2 days ago - Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore - GlobeNewsWire
- 11 days ago - Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences - Business Wire
- 18 days ago - Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya - Business Wire
- 23 days ago - Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities - GlobeNewsWire
- 4 weeks ago - Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences - Business Wire
- 5 weeks ago - Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call - Business Wire